{"prompt": "['OSTPDL1', 'Page 68 of 60', 'necessary. After the diagnosis of relapsed or refractory solid tumor is', 'established, we will invite the patient to participate in the OSTPDL1', 'protocol.', 'Throughout the entire treatment period, participants and their parents', 'receive constant education from health professionals at St. Jude and', 'collaborating sites, and are encouraged to ask questions regarding', 'alternatives and therapy. All families have ready access to chaplains,', 'psychologists, social workers, and the St. Jude ombudsperson for', 'support, in addition to that provided by the primary physician and other', 'clinicians involved in their care.', 'We will also obtain verbal assent from children 12 to 14 years old and', 'written assent for all participants > 14 years of age at St. Jude.', 'Collaborating sites will follow institutional guidelines for assent.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-3018 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 69 of 60', '14.3 Consent at Age of Majority', 'Participants who reach the age of majority while on study will be re-', 'consented for continued participation on OSTPDL1 at the time of their', 'next clinic visit after turning 18 year according to Cancer Center and local', 'institutional policy.', '14.4 Consent When English is Not the Primary Language', 'Obtaining consent for non-English speaking participants will follow local', 'institutional policy. At St. Jude, when English is not the participant,', \"parent, or legally authorized representative's primary language, the\", 'investigator or the Social Work department will determine the need for an', \"interpreter. This information will be documented in the participant's\", \"medical record. Either a certified interpreter or the telephone interpreter's\", 'service will be used to translate the consent information. If the short form', 'consent is available in the primary language of the participant, parent or', 'legally authorized representative, this may be utilized to sign consent', 'and joined with a full English consent signed by the research team. The', 'process for obtaining an interpreter and for the appropriate use of an', 'interpreter is outlined on the SJCRH Interpreter Services website, as well', 'as OHSP and CPDMO websites.', '14.5 Collection of Collaborating Institution Consent Forms', \"Signed collaborating institution's consent forms will be faxed to the St.\", 'Jude CPDMO Eligibility Office at 901-595-6265.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-3018 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 70 of 60', '15.0 REFERENCES', '1.', 'Mirabello L, Troisi RJ, Savage SA: Osteosarcoma incidence and', 'survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and', 'End Results Program. Cancer 115:1531-43, 2009', '2.', 'Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: a', 'randomized, prospective trial of the addition of ifosfamide and/or muramyl', 'tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. Journal of', 'clinical oncology : official journal of the American Society of Clinical Oncology', '23:2004-11, 2005', '3.', 'Kempf-Bielack B, Bielack SS, Jurgens H, et al: Osteosarcoma relapse', 'after combined modality therapy: an analysis of unselected patients in the', 'Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559-68, 2005', '4.', 'Kager L, Zoubek A, Potschger U, et al: Primary metastatic', 'osteosarcoma: presentation and outcome of patients treated on neoadjuvant', 'Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21:2011-8', '2003', '5.', 'Ebb D, Meyers P, Grier H, et al: Phase II trial of trastuzumab in', 'combination with cytotoxic chemotherapy for treatment of metastatic', 'osteosarcoma with human epidermal growth factor receptor 2 overexpression:', \"a report from the children's oncology group. J Clin Oncol 30:2545-51, 2012\", '6.', 'Briccoli A, Rocca M, Salone M, et al: High grade osteosarcoma of', 'the extremities metastatic to the lung: long-term results in 323 patients treated', 'combining surgery and chemotherapy, 1985-2005. Surg Oncol 19:193-9, 2010', '7.', 'Bielack SS, Kempf-Bielack B, Branscheid D, et al: Second and', 'subsequent recurrences of osteosarcoma presentation, treatment, and', 'outcomes of 249 consecutive cooperative osteosarcoma study group patients. J', 'Clin Oncol 27:557-65, 2009', '8.', 'Bacci G, Briccoli A, Longhi A, et al: Treatment and outcome of', 'recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated', 'with neoadjuvant chemotherapy. Acta Oncol 44:748-55, 2005', '9.', 'Arndt CA, Koshkina NV, Inwards CY, et al: Inhaled granulocyte-', 'macrophage colony stimulating factor for first pulmonary recurrence of', 'osteosarcoma: effects on disease-free survival and immunomodulation. a', \"report from the Children's Oncology Group. Clin Cancer Res 16:4024-30, 2010\", '10. Pappo AS, Vassal G, Crowley JJ, et al: A phase 2 trial of R1507, a', 'monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in', 'patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma,', 'synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance', 'for Research Through Collaboration study. Cancer 120:2448-56, 2014', '11. Lagmay JP KM, Dang H, Kim A, Hawkins DS, Beatty o, Widemann B,', 'Zwerdlig T, Bomgaars L, Langevin A, Grier HE, Blaney S, Gorlick R, Janeway K:', 'Outcome of recurrent osteosarcoma patients enrolled in seven phase II trials', 'through COG, POG and COG:Learning and moving forward. Presented at the', 'American Society of Clinical Oncology, Chicago, III, 2015', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}